Chronic Hepatitis C
Conditions
Keywords
Chronic hepatitis C,Genotype1,Naïf,bitherapy,Ribavirin adaptation,ribavirin AUC
Brief summary
The aim of this study is to compare two therapeutical strategies concerning the combination therapy (peginterferon alfa-2a and ribavirin) in naïve patients with chronic hepatitis C of genotype 1. Reference strategy corresponding to standards of care recommended by the French consensus conference versus Test strategy corresponding to adaptation strategy of ribavirin dose during the first week according to AUC (area under the curve) of ribavirin plasmatic concentration after the first intake (Day 0) of 600 mg
Interventions
DRUGPeg-interferon alpha 2a and ribavin
Date of ribavirin AUC : Day 0 (beginning of treatment) Bitherapy : Peg-interferon alpha 2a (180 µg/week) with ribavirin (1000 mg/day if weight \< 75 kg and 1200 mg/day if weight ≥ 75 kg). Duration of treatment : 48 weeks Duration of study for patients : 72 weeks
DRUGribavirin with adaptation dose
Date of ribavirin AUC : Day 0 (beginning of treatment) Bitherapy : Peg-interferon alpha 2a (180 µg/week) with ribavirin (dose adaptation) Dose adaptation : Day 7, dependant of result of AUC Ribavirin dose increments : 200 mg, 400 mg or 600 mg with a maximum of 50% of the initial dose (600 mg) applied every 4 days up to the adjusted dose proposed in order to reach the targeted AUC. The maximum daily dose will not exceed 3600 mg Duration of treatment : 48 weeks Duration of study for patients : 72 weeks
Sponsors
Hospices Civils de Lyon
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* 65 years \>Age \>= 18 years * Chronic hepatitis C documented by PCR performed within 3 months and at liver biopsy within 18 months or with serum markers of fibrosis performed within 3 months before inclusion or FibroScan performed * Naive patients for who the physician decided to initiate a combination treatment of chronic hepatitis C with pegylated interferon alfa-2a plus ribavirine * Genotype VHC-1 * Compensated liver disease (Child-Pugh \<=6) * Negative HBsAg test and HIV-RNA test * Negative pregnancy test at baseline in women in age of procreation and efficient contraception all along the treatment period, and up to 7 months after discontinuation for women and men * Signed consent form * Patient with a social cover
Exclusion criteria
* Non HCV liver disease * Non-1 HCV genotype * Organ transplant whatever the organ * Clinical or radiological evidence of liver carcinoma * Severe psychiatric disorder * Non compensated thyroid dysfunction * Woman pregnant or breast-feeding * Recent history of epilepsy (less than 6 months) * Absolute contraindications to one of the drug of combination therapy * Biological abnormalities at pre-treatment check-up, such as: Neutropenia (\<1500/mm³); Haemoglobinemia (\<13 g/dL for men et \<12 g/dL for women); Thrombopenia (\<90 000/mm³); * Kidney failure (creatinine clearance\>70 ml/min) * Hypersensitivity to epoetin or one of its excipients * Treatment by epoetin within 2 months prior inclusion * Chronic cardiac failure (grade III or IV - NYHA classification) * High blood pressure unwell-controlled (SBP \> 180 mmHg during inclusion in spite of hypertension treatment) * Previous history or risk of venous thrombosis * Major surgery within the previous 3 months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Inter-group comparison of sustained virological response rates as defined by the proportion of subjects with a negative PCR HCV-RNA test at Week 72 | 72 weeks |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Efficacy endpoints | 72 weeks | To compare the virological response rate between the two groups: Rapid Virological Response (RVR) at W4, Early Virological Response (EVR) at W12, Virological Response at W24, and End-Of-Treatment response (EOT) at W48 ; To determine the relapse rate (between W48 and W72) and to determine the proportion of patients reaching the target trough ribavirin concentration of 2 mg/L at W4 or W8 after ribavirin dose adjustment in the first 7 days of treatment. |
| safety endpoints | 72 weeks | To investigate the clinical and biological tolerability in patients with dose-adjusted ribavirin compared to those with standard ribavirin doses, the proportion of patients needing EPO co-prescription due to secondary anemia in each group, to estimate the rate of treatment discontinuation due to serious or other relevant adverse events in each group and to determine the proportion of subjects reaching ribavirin trough plasma concentrations considered as toxic (\> 3.5 mg/L) at W4 and W8, in each arm. |
| Economic endpoints | 72 weeks | Comparaison of the test and standard strategies by a medico-economic analysis |
Countries
France
Contacts
Primary ContactMarianne Maynard, MD
Backup ContactVéronique LOUSTAUD-RATTI, MD
Outcome results
None listed